TherapeuticsMD analyst ratings
TherapeuticsMD analyst ratings
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a reiterated with a price target of $0.00 to $1.00. The current price TherapeuticsMD (TXMD) is trading at is $8.27, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/13/2022 | -87.91% | Cantor Fitzgerald | → $1 | Reiterates | → Neutral |
| 06/07/2022 | 20.92% | HC Wainwright & Co. | → $10 | Downgrades | Buy → Neutral |
| 05/06/2022 | -87.91% | Cantor Fitzgerald | $5 → $1 | Downgrades | Overweight → Neutral |
| 03/11/2022 | -69.77% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 11/12/2021 | -63.72% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 08/07/2020 | -85.49% | Jefferies | $1.25 → $1.2 | Downgrades | Hold → Underperform |
| 05/19/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/07/2020 | -39.54% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 04/16/2020 | 81.38% | Stifel | $14 → $15 | Maintains | Buy |
| 02/21/2020 | -27.45% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 08/14/2018 | 226.48% | Cantor Fitzgerald | $26 → $27 | Maintains | Overweight |
| 06/15/2018 | 33.01% | JP Morgan | → $11 | Initiates Coverage On | → Overweight |
| 09/08/2017 | -27.45% | Morgan Stanley | → $6 | Initiates Coverage On | → Equal-Weight |
| 07/21/2017 | 20.92% | Deutsche Bank | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/13/2022 | -87.91% | 坎托·菲茨杰拉德 | → 1 美元 | 重申 | → 中立 |
| 2022 年 7 月 6 日 | 20.92% | HC Wainwright & Co. | → 10 美元 | 降级 | 买入 → 中性 |
| 2022 年 6 月 5 日 | -87.91% | 坎托·菲茨杰拉德 | 5 美元 → 1 美元 | 降级 | 超重 → 中性 |
| 03/11/2022 | -69.77% | HC Wainwright & Co. | $3 → 2.5 美元 | 维护 | 买 |
| 11/12/2021 | -63.72% | HC Wainwright & Co. | 4 美元 → 3 美元 | 维护 | 买 |
| 08/07/2020 | -85.49% | 杰富瑞集团 | 1.25 美元 → 1.2 美元 | 降级 | 持有 → 表现不佳 |
| 2020 年 5 月 19 日 | — | 摩根大通 | 降级 | 超重 → 中性 | |
| 05/07/2020 | -39.54% | HC Wainwright & Co. | 6 美元 → 5 美元 | 重申 | → 购买 |
| 2020 年 4 月 16 日 | 81.38% | Stifel | 14 美元 → 15 美元 | 维护 | 买 |
| 02/21/2020 | -27.45% | HC Wainwright & Co. | 7 美元 → 6 美元 | 维护 | 买 |
| 08/14/2018 | 226.48% | 坎托·菲茨杰拉德 | 26 美元 → 27 美元 | 维护 | 超重 |
| 06/15/2018 | 33.01% | 摩根大通 | → 11 美元 | 启动覆盖范围开启 | → 超重 |
| 09/08/2017 | -27.45% | 摩根士丹利 | → 6 美元 | 启动覆盖范围开启 | → 重量相等 |
| 2017 年 7 月 21 日 | 20.92% | 德意志银行 | → 10 美元 | 启动覆盖范围开启 | → 购买 |
TherapeuticsMD Questions & Answers
TherapeuticsMD 问题与解答
The latest price target for TherapeuticsMD (NASDAQ: TXMD) was reported by Cantor Fitzgerald on July 13, 2022. The analyst firm set a price target for $1.00 expecting TXMD to fall to within 12 months (a possible -87.91% downside). 5 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2022年7月13日公布了TherapeuticSMD（纳斯达克股票代码：TXMD）的最新目标股价。该分析公司将目标股价定为1.00美元，预计TXMD将在12个月内跌至12个月内（可能下跌87.91％）。去年有5家分析公司公布了评级。
The latest analyst rating for TherapeuticsMD (NASDAQ: TXMD) was provided by Cantor Fitzgerald, and TherapeuticsMD reiterated their neutral rating.
坎托·菲茨杰拉德提供了TherapeicsMD（纳斯达克股票代码：TXMD）的最新分析师评级，TherapeicsMD重申了中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on July 13, 2022 so you should expect the next rating to be made available sometime around July 13, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与TherapeuticSMD的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。TherapeuticSMD的最新评级是在2022年7月13日公布的，因此您应该预计下一个评级将在2023年7月13日左右公布。
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a reiterated with a price target of $0.00 to $1.00. The current price TherapeuticsMD (TXMD) is trading at is $8.27, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但重申了最新的TherapeuticSMD（TXMD）评级，目标股价为0.00美元至1.00美元。TherapeuticSMD（TXMD）目前的交易价格为8.27美元，超出了分析师的预期区间。
